Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2025;13(8):10 BMC Cancer . 2025 Feb 19;25(1):302.What this means for my practice?
Regorafenib offers a modest improvement in short-term disease control for patients with metastatic or recurrent bone sarcomas, though it does not improve long-term survival and increases the risk of adverse effects. Clinicians should weigh its progression-free survival benefits against its tolerability. A key limitation is the small sample size and heterogeneity in sarcoma subtypes, which restricts generalizability and precludes subgroup analysis.
Study Summary
Five randomized controlled trials including 179 patients with metastatic or recurrent bone sarcomas were included in this systematic review and meta-analysis comparing regorafenib monotherapy vs. placebo. Pooled outcomes of interest included 3- and 6-month progression-free survival (PFS), overall survival (OS) at multiple timepoints, and adverse events (AEs). Regorafenib significantly improved 3-month PFS and 6-month PFS with no improvement in OS. Adverse events were more frequent in the regorafenib group. The findings suggest regorafenib improves short-term disease control but not long-term survival, with a higher incidence of manageable side effects.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
